What is the recommended treatment for vaginal candidiasis in a healthy non‑pregnant adult woman, and how should management be modified for pregnant patients, diabetics, immunosuppressed individuals, or those with recurrent infections?

Treatment of Vaginal Candidiasis

For uncomplicated vaginal candidiasis in a healthy non-pregnant adult woman, prescribe either a single 150 mg oral dose of fluconazole or a short-course (3–7 day) topical azole regimen; both achieve >90% cure rates and are equally effective first-line options. 1, 2

Diagnostic Confirmation Before Treatment

• Confirm diagnosis with wet-mount microscopy using 10% potassium hydroxide to visualize budding yeast or pseudohyphae, and verify vaginal pH ≤4.5 to exclude bacterial vaginosis (pH >4.5) or trichomoniasis. 1, 2

• Obtain vaginal cultures when microscopy is negative but clinical suspicion remains high, when symptoms persist after appropriate therapy, or when the patient has ≥4 episodes per year to identify non-albicans species. 1, 2

• Do not treat asymptomatic colonization; 10–20% of women harbor Candida without infection. 2

First-Line Treatment Options for Uncomplicated Disease

Oral Therapy

• Fluconazole 150 mg as a single oral dose is the most convenient regimen. 1, 2, 3

Topical Therapy (3-Day Regimens)

• Miconazole 200 mg vaginal suppository once daily for 3 days 1, 2, 4
• Terconazole 0.8% cream 5 g intravaginally once daily for 3 days 1, 2
• Terconazole 80 mg vaginal suppository once daily for 3 days 1, 2

Topical Therapy (7-Day Regimens)

• Clotrimazole 1% cream 5 g intravaginally once daily for 7 days 1, 2
• Miconazole 2% cream 5 g intravaginally once daily for 7 days 1, 2, 4
• Terconazole 0.4% cream 5 g intravaginally once daily for 7 days 1, 2

All topical regimens listed above achieve equivalent efficacy to oral fluconazole; no single agent is superior. 1

Management of Complicated Vulvovaginal Candidiasis

Severe Vulvar Inflammation

• When marked vulvar erythema, edema, excoriation, or fissures are present, avoid single-dose regimens. Instead, prescribe either:
  • Extended topical azole therapy for 7–14 days (any regimen listed above) 1, 2
  • OR fluconazole 150 mg orally every 72 hours for a total of 2–3 doses 1, 2

Recurrent Vulvovaginal Candidiasis (≥4 Episodes/Year)

Use a two-phase treatment strategy:

Induction Phase (10–14 Days)

• Either daily topical azole therapy for 10–14 days OR fluconazole 150 mg orally with a repeat dose after 72 hours 1, 2

Maintenance Phase (6 Months)

• Fluconazole 150 mg orally once weekly for 6 months controls symptoms in >90% of patients during treatment. 1, 2

• After discontinuation of the 6-month maintenance course, anticipate a 40–50% recurrence rate. 1, 2, 5

Non-Albicans Candida Species (Especially C. glabrata)

• C. glabrata accounts for 10–20% of recurrent cases and shows reduced susceptibility to standard azoles. 1, 2, 5

• First-line therapy for C. glabrata: boric acid 600 mg intravaginal gelatin capsule once daily for 14 days achieves 64–72% mycological cure versus 29–33% with fluconazole. 1, 2, 5, 6, 7

• Second-line options for C. glabrata: topical 17% flucytosine cream alone or combined with 3% amphotericin B cream daily for 14 days (requires compounding). 1, 5

• Nystatin 100,000 U vaginal suppository daily for 14 days is an alternative but less effective than boric acid. 1

Special Populations

Pregnant Women

• Avoid oral fluconazole at any dose during pregnancy due to associations with spontaneous abortion and congenital malformations. 2, 5, 6

• Use only topical azole therapy for 7 days (clotrimazole 1% cream, miconazole 2% cream, or terconazole 0.4% cream, each 5 g intravaginally daily). 2, 5, 6

• Boric acid is contraindicated in pregnancy. 5

Diabetic Patients

• Diabetes classifies the infection as "complicated" due to immunologic factors, necessitating extended therapy. 5, 6

• Diabetic women with VVC have a higher prevalence of C. glabrata (54.1% vs. 22.6% in non-diabetics) and show limited response to single-dose fluconazole. 8

• For diabetic patients with confirmed C. glabrata, prescribe boric acid 600 mg intravaginally daily for 14 days rather than oral fluconazole. 6, 7

• For diabetic patients with C. albicans, use extended topical azole therapy for 7–14 days or fluconazole 150 mg every 72 hours for 2–3 doses. 6

Immunosuppressed Individuals (Including HIV-Positive Women)

• Treatment regimens and clinical response are identical to immunocompetent women; therapy does not need modification based solely on HIV status. 1, 2, 5

• Episodes may be more severe and more frequently recurrent in patients with advanced immunosuppression, but standard regimens remain appropriate. 1

Critical Pitfalls to Avoid

• Do not initiate therapy without microscopic confirmation; clinical symptoms overlap significantly with bacterial vaginosis and trichomoniasis, and self-diagnosis is accurate in only 30–50% of cases. 1, 2, 5

• Do not use single-dose regimens for severe vulvar inflammation; these cases require 7–14 day therapy. 1, 2

• Do not treat sexual partners routinely; vulvovaginal candidiasis is not a sexually transmitted infection and partner treatment does not reduce recurrence. 2, 5

• Do not prescribe nystatin for C. glabrata infections; it is ineffective. 1, 5

• Do not discontinue the 6-month maintenance regimen prematurely for recurrent VVC; completing the full course maximizes the chance of prolonged remission. 2

When to Obtain Cultures

• Obtain vaginal cultures in the following situations:

  • Microscopy is negative but clinical suspicion remains high 1, 2
  • Symptoms persist after appropriate therapy 2, 5
  • The patient has ≥4 episodes per year (recurrent VVC) 1, 2
  • Treatment failure with standard azoles (to detect C. glabrata or other non-albicans species) 1, 2, 5

• Species identification is essential because non-albicans Candida show reduced susceptibility to standard azoles and require alternative treatment approaches. 1, 2, 5

Follow-Up Recommendations

• No routine follow-up is needed if asymptomatic after treatment. 5

• Patients should seek further medical evaluation if:

  • Symptoms persist after completing therapy 2, 5
  • Symptoms recur within 2 months 2, 5
  • They experience ≥4 episodes within a 12-month period (meeting recurrent VVC criteria) 2